Skip to main content
SpringerLink
Log in

The Multiple Myeloma Research Foundation's evolving focus on drug R&D

  • Commentary
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

The Multiple Myeloma Research Foundation (MMRF) has developed innovative, collaborative business models to reshape the R&D enterprise with the single-minded focus of accelerating the development of new treatments for patients to extend their lives and lead to a cure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Dilts, D. & Sandler, A. J. Clin. Oncol. 24, 4545–4551 (2006).

    Article  Google Scholar 

  2. Wear, S. et al. Proc. American Society of Hematology, San Diego, CA, Dec. 2011 (Abstract #1024)

  3. Chapman, M.A. et al. Nature 471, 467–472 (2011).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Kathy Giusti is the Founder and CEO of the Multiple Myeloma Research Foundation, Norwalk, Connecticut, USA.,

    Kathy Giusti

Authors
  1. Kathy Giusti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kathy Giusti.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Giusti, K. The Multiple Myeloma Research Foundation's evolving focus on drug R&D. Nat Biotechnol 30, 600–603 (2012). https://doi.org/10.1038/nbt.2297

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.2297

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation